The TRAIN-HEART consortium, funded by the European Commission (2019-2023), is made up to train a league of 15 promising fellows that harness novel insights in the pathogenesis of ischemic heart failure, study the therapeutic potential of existing RNA therapeutics and improve its efficacy by the design of novel drug delivery systems.


TRAIN-HEART brings together leading academic teams and (biotech) companies covering various disciplines ranging from fundamental research to clinical pharmacology and gene therapy to drug delivery applications, have teamed up in the European Union.

Research Programme

The TRAIN-HEART network aims to gain viable insight in the pathogenesis of ischemic heart failure which will serve as a basis for drug discovery and drug delivery efforts that aim to therapeutically target specific molecules and mechanisms within cardiomyocytes for the treatment of ischemic heart failure.  


If you have any questions you can fill in the form or mail us directly:


Outstanding webinar on Biocompatible Drug Delivery Systems organized by Université Claude Bernard Lyon 1

The full programme of the webinar:

Introduction to the webinar (Alexandra Montembault)

Part 1: General concepts (Thierry Delair)

  • The rationale for Drug Delivery systems
  • Targeting, what for and how?
  • Routes of administration and physiological barriers
  • Safety and regulations

Part 2: The formulation of DDS (Thierry Delair)

  • Polymers, polysaccharides and proteins II-2. Polymerdrugs
  • From monomers to Nano-scaled DDS
  • Nano-scaled DDS by macromolecular assembly
  • Loading the Active Pharmaceutical Ingredient and the targeting species

Part 3: Examples

  • Nano-scaled delivery of anti-viral drugs for HAART (Thierry Delair)
  • Non-viral vectors for gene delivery (Hussein Genedy)
  • Nano-scaled systems for vaccine delivery (Thierry Delair)
  • Future and prospects

Part 4: Multi functional nano-scaled delivery systems towards theranostics (Arnaud Favier)